Gareth Sanger

Q: What Schools Are Affiliated With Gareth Sanger

Gareth Sanger is affiliated with the following schools: University of Sheffield, University of Oxford, Newcastle University, Queen Mary University of London, University of Manchester

Gareth Sanger's AcademicInfluence.com Rankings

Gareth Sanger

Medical

#2675

World Rank

#3106

Historical Rank

Pharmacology

#317

World Rank

#368

Historical Rank

medical Degrees

Download Badge

Medical

Gareth Sanger's Degrees

PhD Pharmacology University of Oxford
Bachelors Pharmacology University of Oxford

Why Is Gareth Sanger Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Gareth J. Sanger is a British pharmacologist. Sanger was a research fellow at King's College Hospital Medical School from 1977 to 1990. He then spent a period in the pharmacological industry, before being appointed, in 2009, Professor of Neuropharmacology, at Queen Mary University of London.

(See a Problem?)

Gareth Sanger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism (1986) (325)
Neuropharmacology of emesis induced by anti-cancer therapy. (1988) (324)
Cloning and functional expression of a human orthologue of rat vanilloid receptor-1 (2000) (298)
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview (2017) (266)
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors (2021) (212)
Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). (1989) (211)
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. (1988) (210)
Treatment of nausea and vomiting: Gaps in our knowledge (2006) (195)
Dorsal root ganglion neurons show increased expression of the calcium channel α2δ-1 subunit following partial sciatic nerve injury (2001) (178)
Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin (2003) (174)
Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. (2002) (163)
The relationship between the effects of short‐chain fatty acids on intestinal motility in vitro and GPR43 receptor activation (2007) (154)
The Concise Guide to Pharmacology 2013/14: Overview (2013) (143)
Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. (1987) (124)
5-Hydroxytryptamine (5-HT3) receptor antagonists. 1. Indazole and indolizine-3-carboxylic acid derivatives. (1990) (113)
Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract (2007) (111)
Increased gut cholinergic activity and antagonism of 5‐hydroxytryptamine M‐receptors by BRL 24924: potential clinical importance of BRL 24924 (1987) (109)
METABOLITES OF ARACHIDONIC ACID FORMED BY HUMAN GASTROINTESTINAL TISSUES AND THEIR ACTIONS ON THE MUSCLE LAYERS (1981) (109)
Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat (2006) (108)
Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. (2001) (98)
The effects of granisetron, ICS 205–930 and ondansetron on the visceral pain reflex induced by duodenal distension (1990) (97)
The translational value of rodent gastrointestinal functions: a cautionary tale. (2011) (97)
Ghrelin and motilin receptors as drug targets for gastrointestinal disorders (2016) (96)
Quantitative mRNA analysis of five C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. (2001) (93)
Hormones of the gut–brain axis as targets for the treatment of upper gastrointestinal disorders (2008) (93)
Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents (2006) (90)
Identification of genes for the ghrelin and motilin receptors and a novel related gene in fish, and stimulation of intestinal motility in zebrafish (Danio rerio) by ghrelin and motilin. (2008) (84)
Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon (2008) (80)
Pica—A model of nausea? Species differences in response to cisplatin (2005) (79)
Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin (2006) (79)
Nausea and the quest for the perfect anti-emetic. (2014) (78)
5-hydroxytryptamine and the gastrointestinal tract: where next? (2008) (76)
The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin (2013) (76)
Characterisation of 5‐HT3C, 5‐HT3D and 5‐HT3E receptor subunits: evolution, distribution and function (2009) (74)
The guinea‐pig distal colon ‐ a sensitive preparation for the investigation of 5‐HT4 receptor‐mediated contractions (1993) (72)
Endocannabinoids and the gastrointestinal tract: what are the key questions? (2007) (72)
Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases. (2008) (72)
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function (2020) (72)
Regional‐ and agonist‐dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists (2012) (71)
Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain (2004) (70)
Development of drugs for gastrointestinal motor disorders: translating science to clinical need (2008) (69)
The effects of SB 204070, a highly potent and selective 5‐HT4 receptor antagonist, on guinea‐pig distal colon (1994) (68)
The rabbit motilin receptor: molecular characterisation and pharmacology (2003) (68)
Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. (2007) (67)
5‐HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle (2006) (66)
Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists (2013) (66)
Caffeine induces gastric acid secretion via bitter taste signaling in gastric parietal cells (2017) (64)
The effect of sympathetic nerve stimulation on serum gastrin, gastric acid secretion and mucosal blood flow responses to meat extract stimulation in anaesthetized cats. (1975) (63)
Evidence for the involvement of central 5‐HT7 receptors in the micturition reflex in anaesthetized female rats (2003) (60)
Prokineticin-2, motilin, ghrelin and metoclopramide: prokinetic utility in mouse stomach and colon. (2005) (59)
Anxiolytic-like Actions of the Selective 5-HT4 Receptor Antagonists SB 204070A and SB 207266A in Rats (1997) (59)
Pharmacological characterization of the vanilloid receptor in the rat dorsal spinal cord (1997) (59)
5-Hydroxytryptamine-3 Receptor Antagonists (1993) (59)
Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. (2007) (57)
Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans (2015) (57)
Differences between 5‐HT3 receptor antagonists in modulation of visceral hypersensitivity (1995) (56)
Intestinal anti‐nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action (2003) (56)
The relationship between gastric motility and nausea: gastric prokinetic agents as treatments. (2013) (56)
Translating 5‐HT4 receptor pharmacology (2009) (56)
A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research (2018) (52)
GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility (2009) (51)
New antiemetic drugs. (1990) (50)
Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: A model of chemotherapy-related malaise? (2006) (49)
The prokinetic-like activity of ghrelin in rat isolated stomach is mediated via cholinergic and tachykininergic motor neurones. (2006) (47)
Increased defecation during stress or after 5‐hydroxytryptophan: selective inhibition by the 5‐HT4 receptor antagonist, SB‐207266 (2000) (46)
GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. (2009) (44)
Thermal, but not mechanical, nociceptive behavior is altered in the Zucker Diabetic Fatty rat and is independent of glycemic status. (1999) (43)
The role of endogenous opioids in the control of gastrointestinal motility: predictions from in vitro modelling (2004) (41)
COVID‐19, nausea, and vomiting (2020) (40)
Effects of metoclopramide and domperidone on cholinergically mediated contractions of human isolated stomach muscle (1985) (39)
Oral administration of a centrally acting ghrelin receptor agonist to conscious rats triggers defecation (2009) (38)
Functional and in situ hybridization evidence that preganglionic sympathetic vasoconstrictor neurons express ghrelin receptors (2010) (38)
Selective and functional 5‐hydroxytryptamine4 receptor antagonism by SB 207266 (1996) (37)
Substituted benzamides with conformationally restricted side chains. 5. Azabicyclo[x.y.z] derivatives as 5-HT4 receptor agonists and gastric motility stimulants. (1993) (37)
N-[(1-butyl-4-piperidinyl)methyl]-3,4dihydro-2H-[1,3]oxazino[3,2- a]indole10-carboxamide hydrochloride: the first potent and selective 5-HT4 receptor antagonist amide with oral activity. (1995) (36)
Fenamates may antagonize the actions of prostaglandin endoperoxides in human myometrium. (1979) (35)
Translational neuropharmacology: the use of human isolated gastrointestinal tissues (2013) (35)
Differences between the abilities of tegaserod and motilin receptor agonists to stimulate gastric motility in vitro (2007) (35)
UDP-glucose modulates gastric function through P2Y14 receptor-dependent and -independent mechanisms. (2009) (35)
Ex vivo study of human visceral nociceptors (2016) (34)
Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans (2010) (34)
The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. (2004) (33)
Antagonism by SB 204070 of 5‐HT‐evoked Contractions in the Dog Stomach: an In‐vivo Model of 5‐HT4 Receptor Function (1995) (32)
Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia (2008) (31)
Activation of a myenteric 5‐hydroxytryptamine‐like receptor by metoclopramide (1987) (31)
Drugs acting at 5‐HT4, D2, motilin, and ghrelin receptors differ markedly in how they affect neuromuscular functions in human isolated stomach (2014) (30)
Three different ways in which 5‐hydroxytryptamine can affect cholinergic activity in guinea‐pig isolated ileum (1985) (30)
Increased defaecation caused by 5-HT4 receptor activation in the mouse. (1996) (30)
Anti-emetic and emetic effects of erythromycin in Suncus murinus: role of vagal nerve activation, gastric motility stimulation and motilin receptors. (2013) (30)
Intrinsic nerve circuits of the gastrointestinal tract: identification of drug targets. (2002) (29)
Ghrelin and motilin receptor agonists: time to introduce bias into drug design (2014) (29)
5-HT4 receptor antagonism does not affect motor and reward mechanisms in the rat. (1998) (28)
Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate. (2009) (28)
The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying (2016) (28)
Constipation Evoked by 5‐HT3‐Receptor Antagonism: Evidence for Heterogeneous Efficacy among Different Antagonists in Guinea‐pigs (1994) (27)
GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs (2011) (26)
Cholinergic interactions between donepezil and prucalopride in human colon: potential to treat severe intestinal dysmotility (2013) (26)
ANTAGONISM BY FENAMATES OF PROSTAGLANDIN ACTION IN GUINEA‐PIG AND HUMAN ALIMENTARY MUSCLE (1980) (26)
Regional differences in the responses to prostanoids of circular muscle from guinea‐pig isolated intestine (1980) (24)
In Vitro Techniques for the Study of Gastrointestinal Motility (1982) (24)
ANTAGONISM OF PROSTANOID‐INDUCED CONTRACTIONS OF RAT GASTRIC FUNDUS MUSCLE BY SC‐19220, SODIUM MECLOFENAMATE, INDOMETHACIN OR TRIMETHOQUINOL (1980) (24)
GABA(B) receptor function in the ileum and urinary bladder of wildtype and GABA(B1) subunit null mice. (2002) (24)
5-Hydroxytryptamine3 receptor antagonism modulates a noxious visceral pseudoaffective reflex (1995) (24)
Potentiation by cholinesterase inhibitors of cholinergic activity in rat isolated stomach and colon. (2008) (23)
Translating 5-HT 4 receptor pharmacology (2009) (22)
Benzotriazinones as "virtual ring" mimics of o-methoxybenzamides: novel and potent 5-HT3 receptor antagonists. (1990) (22)
The Hungry Stomach: Physiology, Disease, and Drug Development Opportunities (2010) (21)
Ghrelin and Motilin Control Systems in GI Physiology and Therapeutics. (2016) (20)
Synergy between 5‐HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach (2008) (20)
Regionally selective cholinergic stimulation by BRL 24924 in the human isolated gut. (1988) (19)
Do 5‐HT4 Receptors Mediate the Intestinal Secretory Response to 5‐HT in Rat In‐vivo? (1995) (19)
Hypersensitivity and Hyperreactivity in the Irritable Bowel Syndrome: An Opportunity for Drug Discovery (1999) (19)
Effects of the peripherally acting NK3 receptor antagonist, SB‐235375, on intestinal and somatic nociceptive responses and on intestinal motility in anaesthetized rats (2004) (19)
Synthesis and pharmacological activity of metabolites of the 5-HT(4) receptor antagonist SB-207266. (2001) (18)
Changes in neuromuscular structure and functions of human colon during ageing are region-dependent (2018) (18)
BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties (1993) (18)
Inhibition of colonic motility and defecation by RS‐127445 suggests an involvement of the 5‐HT2B receptor in rodent large bowel physiology (2009) (18)
Regionally dependent neuromuscular functions of motilin and 5‐HT4 receptors in human isolated esophageal body and gastric fundus (2014) (18)
The identification of and rationale for drugs which act at the motilin receptor. (2009) (18)
Stimulation of Canine Gastric Motility by BRL 24924, a New Gastric Prokinetic Agent (1990) (18)
Rank-order inhibition by ω-conotoxins in human and animal autonomic nerve preparations (2000) (17)
SB-204070: 5-HT4 receptor antagonists and their potential therapeutic utility (1994) (17)
5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats (1999) (17)
Pharmacological Characterization of the Vanilloid Receptor in the Rat Isolated Vas Deferens (1996) (17)
The Effects of Various Peptides on Human Isolated Gut Muscle (1992) (16)
Neuromedin U can exert colon‐specific, enteric nerve‐mediated prokinetic activity, via a pathway involving NMU1 receptor activation (2007) (16)
GR46611 potentiates 5-HT1A receptor-mediated locomotor activity in the guinea pig. (1999) (16)
Dopamine Antagonists as Anti-Emetics and as Stimulants of Gastric Motility (1984) (16)
Identification of small molecule agonists of the motilin receptor. (2008) (15)
5-HT3 RECEPTOR ANTAGONISTS (1989) (15)
Motilin receptor neuropharmacology: revised understanding. (2012) (15)
The effects of various pharmacological agents on the metoclopramide-induced increase in cholinergic-mediated contractions of rat isolated forestomach. (1985) (15)
Increased plasma ghrelin following infliximab in Crohn’s disease (2009) (15)
Potent achiral agonists of the growth hormone secretagogue (ghrelin) receptor. Part 2: Lead optimisation. (2008) (14)
From metoclopramide to selective gut motility stimulants and 5-HT3 receptor antagonists. (1988) (14)
Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride? (2010) (14)
RQ-00201894: A motilin receptor agonist causing long-lasting facilitation of human gastric cholinergically-mediated contractions. (2016) (14)
Constipation Evoked by 5-HT3 Receptor Antagonists (1991) (13)
SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis. (2004) (13)
5-Hydroxytryptamine and Cholinergic Function in the Gastrointestinal Tract (1990) (13)
Analysis of pancreatic polypeptide cDNA from the house musk shrew, Suncus murinus, suggests a phylogenetically closer relationship with humans than for other small laboratory animal species (2003) (13)
Acidic Lipids: Prostaglandins (1982) (12)
Identification of arachidonic acid metabolites extracted from human uterus, and their effects on the isolated myometrium (1981) (12)
Site-specific splice variation of the human P2X4 receptor (1999) (12)
Human native kappa opioid receptor functions not predicted by recombinant receptors: Implications for drug design (2016) (12)
Potent achiral agonists of the ghrelin (growth hormone secretagogue) receptor. Part I: Lead identification. (2007) (12)
Therapeutic Applications of 5-HT4 Receptor Agonists and Antagonists (1998) (11)
Mechanisms by which Metoclopramide can Increase Gastrointestinal Motility (1984) (11)
Prostacyclin relaxes the longitudinal muscle of human isolated stomach and antagonizes contractions to some prostanoids [proceedings]. (1980) (11)
Analysis of factors that determine the compliance of rat jejunum to distension in vivo (2003) (11)
The discovery of biaryl carboxamides as novel small molecule agonists of the motilin receptor. (2008) (11)
A prostaglandin analogue which potently relaxes human uterus but not gut muscle. (1982) (11)
Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders (2010) (10)
Increased gastric cholinergic activity evoked by 5-hydroxy-L-tryptophan in the rat. (1986) (10)
Chapter 21. Gastrointestinal Motility Enhancing Agents (1988) (10)
Overview Central & Peripheral Nervous System: 5-HT4 receptor antagonists (1994) (10)
Secoverine hydrochloride is a muscarinic antagonist in human isolated gastrointestinal muscle and myometrium (1981) (10)
A single pretreatment with MK-801 or cocaine enhances their locomotor stimulant effects in rats (1999) (9)
Investigational drug therapies for the treatment of gastroparesis (2017) (9)
Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. (2015) (9)
Effects of NMDA receptor antagonists on visceromotor reflexes and on intestinal motility, in vivo (2007) (9)
Endogenous Opioids and the Gastrointestinal Tract (2005) (9)
Inhibition by tianeptine of neuronally mediated contractions in the rat isolated gastrointestinal tract. (2008) (9)
The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression (2012) (9)
The relationship between propagated contractions and pseudoaffective changes in blood pressure in response to intestinal distension (2001) (9)
5-HT 3 receptor antagonists (1989) (9)
PINANE THROMBOXANE A2 ANALOGUES ARE NON‐SELECTIVE PROSTANOID ANTAGONISTS IN RAT AND HUMAN STOMACH MUSCLE (1982) (8)
Defensive and pathological functions of the gastrointestinal NK3 receptor. (2006) (8)
GASTROINTESTINAL MOTILITY ENHANCING AGENTS (1988) (8)
Reversal of Pathogen-Induced Barrier Defects in Intestinal Epithelial Cells by Contra-pathogenicity Agents (2020) (8)
Prostanoids formed by human gastrointestinal tissues and their effects on muscle activity. (1983) (8)
Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret (2005) (7)
Functional and anatomical deficits in visceral nociception with age: mechanism of silent appendicitis in the elderly? (2019) (7)
Rank-order inhibition by omega-conotoxins in human and animal autonomic nerve preparations. (2000) (7)
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function (2012) (7)
The 5-HT4 receptor antagonist SB 204070 inhibits the contractile response to 5-HT in the dog Heidenhain pouch. (1993) (7)
The effects of prostaglandin D2 on the circular muscle of guinea-pig isolated ileum and colon [proceedings]. (1978) (7)
Functional brain networks and neuroanatomy underpinning nausea severity can predict nausea susceptibility using machine learning (2019) (7)
The effect of PGE1 on peristalsis and on perivascular nerve inhibition of peristaltic activity in guinea‐pig isolated ileum (1978) (7)
Modulation of peristalsis by NK3 receptor antagonism in guinea-pig isolated ileum is revealed as intraluminal pressure is raised. (2007) (7)
C-type natriuretic peptide is a pivotal regulator of metabolic homeostasis (2022) (6)
The Benefits of Olanzapine in Palliating Symptoms (2020) (6)
5-HT(1B/D) receptor agonist, SKF99101H, induces locomotor hyperactivity in the guinea pig. (2000) (6)
Molecular Approaches to the Study of Pain (2003) (6)
Drugs targeting functional bowel disorders: insights from animal studies. (2002) (6)
Gastrointestinal neuropharmacology: identification of therapeutic targets. (2002) (6)
The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor. (2009) (5)
The Relationship Between Symptom Improvement and Gastric Emptying in the Treatment of Gastroparesis: Remember the Pharmacology (2014) (5)
Ghrelin and motilin receptor agonists: a long and winding misconception (2013) (5)
N‐((1‐Butyl‐4‐piperidinyl)methyl)‐3,4‐dihydro‐2H‐(1,3)oxazino(3,2‐a) indole‐10‐carboxamide Hydrochloride: The First Potent and Selective 5‐ HT4 Receptor Antagonist Amide with Oral Activity. (1996) (5)
Indazole and indoline as aromatic bioisosteres in the imidazole class of serotonin 5-HT3 receptor antagonists (1992) (5)
Atypical 5-HT receptors in guinea-pig isolated ileum. (1989) (4)
Making Sense of Emesis, Pruritus, 5-HT and 5-HT3Receptor Antagonists (1996) (4)
Identification and Distribution of Arachidonic Acid Metabolites in the Human Gastrointestinal Tract, and the Ways in Which Some of these Affect the Longitudinal Muscle (1981) (4)
PGI2 or PGE2 selectively antagonize responses to excitatory PGs in human isolated myometrium. (1980) (4)
Locomotor activity detects subunit-selective effects of agonists and decahydroisoquinoline antagonists at AMPA/kainic acid ionotropic glutamate receptors in adult rats (2005) (4)
Aryl sulphonyl amides as potent agonists of the growth hormone secretagogue (ghrelin) receptor. (2009) (4)
Gastrointestinal Pharmacology: Challenges Ahead (2010) (4)
Novel approaches and clinical opportunity for gastrointestinal prokinetic drugs (2007) (3)
Prostacyclin and prostaglandin E2 selectively antagonize responses of human isolated myometrium to excitatory prostaglandins [proceedings]. (1979) (3)
Techniques for Studying Gastrointestinal Motility in Vitro (1984) (3)
Research report Dorsal root ganglion neurons show increased expression of the calcium channel a2d-1 subunit following partial sciatic nerve injury (2001) (3)
WITHDRAWN: Demonstration of functional neuronal B3-adrenoceptors within the enteric nervous system (2007) (3)
A multi-parameter approach to measurement of spontaneous myogenic contractions in human stomach: Utilization to assess potential modulators of myogenic contractions. (2022) (3)
Trimethoquinol selectively antagonises longitudinal muscle contractions of rat isolated gastric fundus to thromboxane B2 and epoxymethano analogues of PGH2 [proceedings]. (1979) (3)
5‐hydroxyindalpine, an agonist at the putative 5‐HT1P receptor, has no activity on human recombinant monoamine receptors but accelerates distension‐induced peristalsis in mouse isolated colon (2009) (3)
PWE-051 Studies of the psychophysiological markers and the brain processing of nausea in healthy humans using a novel virtual reality video (2012) (3)
Prolonged anti‐emetic activity and 5‐HT3‐receptor antagonism by BRL 46470 in conscious ferrets (1994) (3)
Some mechanisms which may modulate noradrenaline release in guinea‐pig isolated ileum (1980) (3)
Evidence that central 5-HT7 receptors are involved in the control of micturition in urethane anaesthetized rats (2003) (2)
Excitatory and inhibitory neuroanally-mediated actiens of orexin-A and melaniaconcentrating hormone (MCH) in human isolated colon (2001) (2)
Evidence for tetrodotoxin‐resistant spontaneous myogenic contractions of mouse isolated stomach that are dependent on acetylcholine (2021) (2)
Inhibition of Neuromuscular Contractions of Human and Rat Colon by Bergamot Essential Oil and Linalool: Evidence to Support a Therapeutic Action (2020) (2)
Farnesoid X receptor ‐ a molecular predictor of weight loss after vertical sleeve gastrectomy? (2019) (2)
New target profiling for gastrointestinal disorders: where are we going? (2012) (2)
Metoclopramide : A Template for Drug Discovery (2017) (2)
Identifying human biomarkers of nausea for refining animal studies on emesis (2011) (2)
Prostanoid Agonists and Antagonists: Differentiation of Prostanoid Receptors in the Gut (1981) (2)
A proposal for rational drug class terminology: A gastrointestinal perspective (2022) (2)
A Novel Phenotype of Glycogen Storage Disease Presenting as Gastrointestinal Neuromuscular Disease (2011) (2)
Total collagen content and distribution is increased in human colon during advancing age (2022) (2)
Synergistic augmentation of rhythmic myogenic contractions of human stomach by arginine vasopressin and adrenaline: Implications for the induction of nausea (2022) (2)
Motilin receptor (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database (2020) (2)
PWE-003 Vasopressin contracts human isolated stomach muscle: possible role in nausea? (2012) (1)
Modulators of 5-HT functions in the treatment of gastrointestinal disorders (1998) (1)
Sodium flufenamate antagonises the potentiation by prostaglandins of noradrenaline-induced vasoconstriction in rat mesentery [proceedings]. (1979) (1)
OC-072 Identification of psychophysiological biomarkers of nausea using a novel visual induction method (2010) (1)
Responses to E-capsaicin in detrusor tissue from both wildtype and vanilloid receptor-1 null mice (2001) (1)
T1381 Inhibition of Colonic Motility and Defecation By RS-127445 Suggests Involvement of the 5-HT2b Receptor in Large Bowel Physiology (2008) (1)
Effect of old age on the subpopulations of enteric glial cells in human descending colon (2022) (1)
Review article: An analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis (2023) (1)
Copeptin, a surrogate marker of arginine8 vasopressin, has no ability to modulate human and mouse gastric motility. (2020) (1)
Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions (2022) (1)
PTH-043 Characterisation of motor nerve responses to electrical field stimulation in human isolated colon (2010) (1)
Relationships of Prostaglandins to Gastrointestinal Motility and Secretion (1984) (1)
M2052 Identification of Psychophysiological Biomarkers of Nausea Using a Novel Visual Induction Method (2010) (1)
Neural networks involved in nausea in adult humans: A systematic review (2022) (1)
Facilitation of noncholinergic transmission by Renzapride (BRL24924) in circular muscle of guinea pig ileum. (1992) (1)
GABAb receptor-mediated inhibition of cholinergic function in mouse ileum requires the GABAb1 subunit (2001) (1)
Why is motilin active in some studies with mice, rats, and guinea pigs, but not in others? Implications for functional variability among rodents (2022) (1)
5-HT3 and 5-HT4 receptors in vomiting and gut movement. (1992) (0)
W2074 Long-Term Consequences of Neo-Adjuvant Chemotherapy for Oesophago-Gastric Cancer On Gastric Contractility and Innervation (2009) (0)
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function (2012) (0)
Trimethoquinol selectively antagonizes contractions of rat gastric fundus to TXB2 and epoxymethano analogs of PGH2. (1980) (0)
Gastrin Receptor Antagonist YF476: Effects on Gastric Acid Secretion, Regulatory Peptides and Receptor Gene Expression in Rats (2011) (0)
Effects of ageing on myenteric neuronal number and neuromuscular function in the human colon (2016) (0)
W1751 Effects of Alosetron On CGRP Release from Colonic Tissue in Rats (2008) (0)
Drugs for treatment of vomiting. (1986) (0)
Efficacy and safety of drugs for gastroparesis: Dopamine receptor antagonists should not be considered as a single pharmacological entity. (2023) (0)
Serum but Not IgG From Patients With Chagas' Disease Relax Naive Human Colon Muscle Without Directly Interfering With Motor Nerve Functions (2011) (0)
CCK2-receptor antagonist YF476 prevents NSAID-induced gastric ulceration through acid inhibition mediated by regulatory peptides (2015) (0)
Neuromedin U-R2 localisation in the mouse gastrointestinal tract and the effects of rat NmU-23 (2003) (0)
小腸および大腸における5-HT4および5-HT3受容体の病態生理学的機能の相違 (1998) (0)
Motilin receptor in GtoPdb v.2021.2 (2021) (0)
Simultaneous recording of pseudoaffective reflexes and motor activity in the jejunum of the anesthetized rat (2001) (0)
Su2110 Brain Processing of Visual Motion Induced Nausea in Healthy Humans (2013) (0)
ANTAGONISM OF PROSTANOID-INDUCEDCONTRACTIONSOF RAT GASTRICFUNDUS MUSCLE BYSC-19220, SODIUM MECLOFENAMATE, INDOMETHACINOR TRIMETHOQUINOL (1980) (0)
antagonist 5-HT4 receptor (1992) (0)
Contractile response to motilin and erythromycin in the lower esophageal sphincter of pigs (2007) (0)
Antagonists 5-HT 4 receptor. (1992) (0)
The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression (2012) (0)
Tu1873 Evidence for Reduced Visceral Nociceptors Activation With Age During Appendicitis (2015) (0)
Tu1811 Cortical & Physiological Responses to Visually Induced Motion Sickness (2014) (0)
A postsynaptic action of prostaglandin E1 on sympathetic responses in guinea-pig ileum [proceedings]. (1976) (0)
The vulnerability of the human taenia coli to alterations in total collagen within the colon of the elderly. (2022) (0)
Drugs for the treatment of emesis. (1986) (0)
Drugs for treatment of emesis, anxietas and "irritable bowel syndrome". (1986) (0)
Piperidyl novel and aminoalkyl antagonist activity 5-HT4 receptor (1992) (0)
Chronic constipation: improved understanding offers a new therapeutic approach (2016) (0)
Some mechanism which may modulate noradrenaline release in guinea-pig isolated ileum. (1980) (0)
Use of 5-HT4 - antagonist for the manufacture of a medicament for treating urinary incontinence (1992) (0)
PTH-264 Preoperative chemoradiotherapy does not appear to have short-term effects on human rectal neuromuscular functions (2015) (0)
Use of certain antagonists of 5-HT3 receptor in the treatment of visceral pain. (1988) (0)
Regionally-Dependent Responses to Both Nerve Stimulation and to Motilin in Human Isolated Esophagus, Stomach, Small and Large Intestine (2011) (0)
Sa2043 Regionally-Specific Changes in Human Colonic Neuromuscular Activity With Advanced Age (2014) (0)
vomit use of granisetron for the treatment of post-operative nausea and (1994) (0)
Gastrointestinal neuropharmacology: identification of therapeutic targets - Editorial overview (2002) (0)
Translation of Motilin and Ghrelin Receptor Agonists into Drugs for Gastrointestinal Disorders (2011) (0)

This paper list is powered by the following services:

Other Resources About Gareth Sanger

What Schools Are Affiliated With Gareth Sanger?

Gareth Sanger is affiliated with the following schools:

Gareth Sanger's Academic­Influence.com Rankings